Last reviewed · How we verify

Priorix Tetra TM 208136

GlaxoSmithKline · Phase 3 active Biologic

Priorix Tetra TM 208136 is a vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Measles, mumps, rubella, and varicella prevention. Also known as: MMRV.

Priorix Tetra is a vaccine that stimulates the body's immune response to protect against measles, mumps, rubella, and varicella.

Priorix Tetra is a vaccine that stimulates the body's immune response to protect against measles, mumps, rubella, and varicella. Used for Measles, mumps, rubella, and varicella prevention.

At a glance

Generic namePriorix Tetra TM 208136
Also known asMMRV
SponsorGlaxoSmithKline
Drug classvaccine
ModalityBiologic
Therapeutic areaInfectious Diseases
PhasePhase 3

Mechanism of action

It works by introducing weakened or inactivated forms of the viruses to the body, which triggers an immune response and helps the body develop immunity against future infections.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Priorix Tetra TM 208136

What is Priorix Tetra TM 208136?

Priorix Tetra TM 208136 is a vaccine drug developed by GlaxoSmithKline, indicated for Measles, mumps, rubella, and varicella prevention.

How does Priorix Tetra TM 208136 work?

Priorix Tetra is a vaccine that stimulates the body's immune response to protect against measles, mumps, rubella, and varicella.

What is Priorix Tetra TM 208136 used for?

Priorix Tetra TM 208136 is indicated for Measles, mumps, rubella, and varicella prevention.

Who makes Priorix Tetra TM 208136?

Priorix Tetra TM 208136 is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

Is Priorix Tetra TM 208136 also known as anything else?

Priorix Tetra TM 208136 is also known as MMRV.

What drug class is Priorix Tetra TM 208136 in?

Priorix Tetra TM 208136 belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is Priorix Tetra TM 208136 in?

Priorix Tetra TM 208136 is in Phase 3.

What are the side effects of Priorix Tetra TM 208136?

Common side effects of Priorix Tetra TM 208136 include Pain, redness, or swelling at the injection site, Fever, Fatigue.

Related